HR Execs on the Move

MetroHealth System

www.metrohealth.org

 
The MetroHealth System is an essential health system committed to providing health care to everyone in Cuyahoga County, Ohio, and improving the health of the community overall. Its 6,700 employees deliver care to everyone at its main campus, just west of downtown Cleveland, and at more than 20 other MetroHealth locations. It also provides health care at more than 20 additional sites in Cuyahoga County through community partnerships such as the School Health Program. MetroHealth is home to Cuyahoga County`s only verified Level I Adult Trauma Center and Level II Pediatric Trauma Center, and it is the only adult and pediatric ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Brandon Doppelheuer
Director of Pharmacy Finance and Profile
Geoffrey Himes
Interim Chief Financial Officer Profile
Craig Richmond
Chief Financial Officer Profile
Kris Kurtz
Chief Financial Officer Profile

Similar Companies

Michele Bally, Pharmaconsult Inc

Michele Bally, Pharmaconsult Inc is a Montral-Ouest, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cardiva Medical

Cardiva Medical, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Cardiva Medical, Inc., please visit www.cardivamedical.com

St. Mary's Innovis Health

St. Mary's Innovis Health is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Detroit Lakes, MN. To find more information about St. Mary's Innovis Health, please visit www.trustedcareforlife.org

Interacoustics USA

Interacoustics USA is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.